Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Small cell lung cancer (SCLC) has typically high sensitivity to chemotherapy and radiotherapy, although greater part of patients with limited disease (LD) and all patients with extended disease (ED) will develop disease relapse or progression, with an overall survival of 2-4 months in case of only best supportive care. Based on response yielded by first-line therapy and relapse-free interval (RFI), interval between first-line treatment completion and disease progression, SCLC are generally divided in two categories: resistant and sensitive. Sensitive patients are those with response to first-line therapy and RFI of 90 days, while resistant patients have no response to first-line chemotherapy or shorter RFI.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi